HQL vs. SCHD

In the year-to-date period, HQL achieves a -0.11% return, which is significantly higher than SCHD's -3.35% return. Over the past 10 years, HQL has underperformed SCHD with an annualized return of 1.69%, while SCHD has yielded a comparatively higher 10.58% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Tekla Life Sciences Investors (HQL) and Schwab US Dividend Equity ETF (SCHD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current HQL Sharpe Ratio is 0.30, which is comparable to the SCHD Sharpe Ratio of 0.35. The chart below compares the historical Sharpe Ratios of HQL and SCHD, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

HQL's dividend yield for the trailing twelve months is around 15.44%, more than SCHD's 3.97% yield.

The maximum HQL drawdown since its inception was -61.69%, which is greater than SCHD's maximum drawdown of -33.37%. Use the drawdown chart below to compare losses from any high point for HQL and SCHD.

Tekla Life Sciences Investors (HQL) has a higher volatility of 9.19% compared to Schwab US Dividend Equity ETF (SCHD) at 4.90%. This indicates that HQL's price experiences larger fluctuations and is considered to be riskier than SCHD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.